Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Starting at lower doses allows assessment of individual tolerance and response before potentially increasing the dose
A FIH trial is a starting point, not a finish line
Inflammatory Bowel Disease Models Research using animal models of IBD (both Crohn's-like and ulcerative colitis-like conditions) has shown BPC-157 [12]: Reduces intestinal inflammation Accelerates mucosal healing Preserves intestinal barrier function Decreases inflammatory cytokine production Prevents fistula formation in some models Intestinal Anastomosis Healing Surgical studies demonstrated that BPC-157 significantly improves the healing of intestinal anastomoses (surgical connections), potentially reducing complications like leakage and stricture formation [13]
These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen
US$ 20.93
US$ 21.34
US$ 27.70
US$ 22.76
US$ 29.75
